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Abstract
Background: The aims of this study were to assess the regulatory review process in South Africa from 2015 to 2017, identify the
key milestones and timelines; evaluate the effectiveness of measures to ensure consistency, transparency, timeliness, and pre-
dictability in the review process; and to provide recommendations for enhanced regulatory practices. Methods: A questionnaire
was completed by the Medicines Control Council (MCC) to describe the organization of the authority, record key milestones and
timelines in the review process and to identify good review practices (GRevPs). Results: Currently, the MCC conducts a full
assessment of quality, efficacy, and safety data in the review of all applications. The overall regulatory median approval time
decreased by 14% in 2017 (1411 calendar days) compared with that of 2016, despite the 27% increase in the number of appli-
cations. However, the MCC has no target for overall approval time of new active substance applications and no targets for key
review milestones. Guidelines, standard operating procedures, and review templates are in place, while the formal implemen-
tation of GRevPs and the application of an electronic document management system are planned for the near future. Conclusions:
As the MCC transitions to the newly established South Africa Health Products Regulatory Authority, it would be crucial for the
authority to recognize the opportunities for an enhanced regulatory review and should consider models such as abridged
assessment, which encompass elements of risk stratification and reliance. It is hoped that resource constraints may then be
alleviated and capacity developed to meet target timelines.
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Introduction
As part of a multicountry study on effective drug regulation,
the World Health Organization (WHO) described 4 dimensions
of medicine regulation, namely, administrative elements, reg-
ulatory functions, level of regulation, and technical elements.1
Further studies by Hill and Johnson recognized that regulators
often operated in an environment with insufficient political
support, resulting in inadequate legislative frameworks and
financial resources, inconsistent application processes, and an
inappropriate regulatory culture.2
During the past decade, regulatory authorities have
acknowledged the need to develop efficient and effective reg-
ulatory review processes.3,4 Regulatory authorities are encour-
aged to facilitate the expedited approval of new medicines
within mandated prerequisites of ensuring patients’ access to
safe, effective, and quality medicines. Regulators face scien-
tific, administrative, and legislative capacity constraints,2
yielding sometimes inoperable regulatory directives, limited
solutions for timely evaluations, and a drive for maintaining
sovereignty.
Many regulators have dedicated resources to improve the
review processes and to develop indicators that go beyond the
measurement of time and speed.3,4 The implementation of
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good review practices (GRevPs) plays a pivotal role in ensuring
consistency, predictability, clarity, and efficiency in the prod-
uct review process5,6 and contributes toward the evaluation of
the performance of the regulatory authority. This review is the
first to be carried out to evaluate the current South African
regulatory review process, as it is has been applied by the
Medicines Control Council (MCC), prior to the establishment
of the South Africa Health Products Regulatory Authority
(SAHPRA).
South Africa and the Medicines
Control Council
The pharmaceutical market in South Africa was valued at
approximately 45 billion Rand (US$3.2 billion) in 2015.7 The
domestic manufacturing pharmaceutical industry almost exclu-
sively produces generic products and the South African phar-
maceutical sector is import dependent.7 In 2013, generic
medicines accounted for 63% of the private pharmaceutical
market and 80% market share in the South African govern-
ment’s pharmaceutical use.7
Over the last 50 years, South Africa has developed a med-
icines regulatory authority with internationally recognized
standing.8 The MCC is described as “the national medicines
regulatory authority of South Africa, which is responsible, in
terms of the Medicines and Related Substances Act, 1965 (Act
101 of 1965), to provide for the monitoring, evaluation, regu-
lation, investigation, inspection, registration, and control of
medicines, scheduled substances, clinical trials, and medical
devices and related matters in the public interest.”9 Currently,
the MCC operates through external experts who are members
of Council Committee structures.8 The staff component of the
Chief Directorate includes doctors, pharmacists, veterinarians,
other scientists, project managers, and administrative staff.8
This study aimed to appraise the regulatory review process
within the MCC, identify key milestones, and evaluate the
review times for new active substances (NASs) and major line
extensions (MLEs), from 2015 to 2017. It is hoped that the
findings will provide a baseline for assessing the changes and
improvements within the MCC, as the authority transitions into
the newly established SAHPRA. This is the first study to eval-
uate the status quo of the regulatory review process of the
MCC, since the promulgation of the Medicines and Related
Substances Act, 1965, as amended on June 1, 2017.10
Study Objectives
The main objectives of this exploratory study were to:
 assess the current regulatory review process in South
Africa;
 identify the key milestones, timelines and stages of the
review process;
 evaluate the effectiveness of the measures used to ensure
consistency, transparency, timeliness, and predictability
in the review process; and
 review the challenges and opportunities for enhanced
regulatory practices in South Africa with a view to
improving patients’ access to innovative medicines.
Methods
This article does not contain any studies with human or animal
subjects performed by any of the authors.
Data Collection Process
The Centre for Innovation in Regulatory Science (CIRS) devel-
oped a questionnaire that has been used to map the key mile-
stones and activities associated with the review processes and
practices within regulatory authorities. Through the use of the
questionnaire, regulatory authorities are able to identify the
models of review that are being used within the authority,
identify target times and the main activities between milestones
for registration, and identify the organization, structure, and the
capacity of the authority.
The questionnaire information on the regulatory review pro-
cess in South Africa was collected during an interview with the
Registrar of Medicines for the MCC. The questionnaire was
completed with a view to analyzing the quality measures that
are currently in place, identify areas of capacity constraints,
and to provide a baseline for the current review process, in
light of the transition to the newly established SAHPRA.11 The
questionnaire consisted of 3 parts, as listed below.
Part I: Organization of the Authority
This documents an introduction to the authority, its current
structure and size, the resources available, and the review mod-
el(s) currently in place.
Part II: Key Milestones in the Registration of Medicines within
the Review Process
This is based on a standard process map that was previously
developed by CIRS, through the study of established and emer-
ging regulatory authorities.12 This process map provided a
detailed description of the pathway of a dossier, through
administrative and technical screening steps, scientific evalua-
tion, and Committee and Council processes. The completed
process map enabled the collection of information in a standar-
dized format, which could be used to simplify the comparison
of the MCC and the current review process with the regulatory
pathways used by other regulatory authorities.
Part III: Good Review Practice
Building quality into the assessment and registration processes
provides an account of the activities and practices, currently in
place at the MCC, which contribute toward improved consis-
tency, transparency, timeliness, and predictability in the regu-
latory review and to the quality of the decision-making process.
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This questionnaire had been developed for use in the analysis
of the regulatory environment in several emerging pharmaceu-
tical markets.12
Results
Part I: Organization of the Authority
The current authority, MCC, was first established in 1965 and
historically operated within the National Department of Health.
Since then, the authority has undergone many changes, includ-
ing its establishment as a 3A Public Entity, known as SAH-
PRA. Provision was made for the restructuring of the authority,
through the amendment of the Medicines and Related Sub-
stances Act, 1965 (Act 101 of 1965), which was published on
June 1, 2017.10
The scope of responsibility of the MCC includes medic-
inal products for human and veterinary use and medical
devices. The MCC is mandated, through the Medicines and
Related Substances Act, 1965 (Act 101 of 1965), to ensure
the efficient, effective, and ethical evaluation or assessment
and registration of medicines and medical devices that meet
the defined standards of quality, safety, efficacy, and perfor-
mance. The MCC also performs licensing activities, inspec-
torate and law enforcement functions, laboratory analysis of
biological products, postmarket surveillance and vigilance
activities, and controls the advertising of medicines and med-
ical devices.
The MCC currently has a staff of approximately 200
full-time personnel, including management, technical and
administrative personnel, and approximately 100 external
consultants. At present, approximately 100 internal and exter-
nal personnel are responsible for the technical evaluation of
applications, which include NASs, generics, biologicals,
veterinary, and complementary products. The majority of the
staff responsible for the regulatory review process are quali-
fied as pharmacists and many of the assessors have postgrad-
uate qualifications.
Model of Assessment in South Africa
Three types of product review assessments are used by regula-
tory authorities: the verification review (type 1), an abridged
review (type 2), and a full review (type 3).12 The MCC con-
ducts a type 3 full assessment in the review of all applications,
including NASs and generics for orthodox, biological, comple-
mentary, and veterinary medicinal products. A full independent
assessment of quality, efficacy, and safety data is performed.
The authority has access to assessors who have the relevant
qualification and technical experience to perform a full assess-
ment of the data provided. The majority of the assessors are
external consultants who are not bound by contractual perfor-
mance agreements. Over the last 2 years, the MCC has made
major changes in building in-house capacity through assistance
from external experts.
Data Requirements and Assessment
The Certificate of Pharmaceutical Product (CPP) is not essen-
tial for registration but a copy of the authorization letter should
be provided if the product has been registered in a reference
country (eg, for fast-track/priority products). Evidence of good
manufacturing practice (GMP) status of the manufacturer and
copies of labeling, for products authorized in reference coun-
tries, are also required. Full quality data (Module 3), full non-
clinical data (Module 4), and full clinical data (Module 5) are
required. A detailed assessment of the data is carried out by
MCC and the relevant assessment reports prepared.
The MCC performs benefit-risk assessments, and the clin-
ical opinion of the authority takes account of differences in
medical culture/practice, ethnic factors, national disease pat-
terns, and unmet medical needs. Where relevant, the authority
will obtain internal assessment reports from other authorities
and publicly available reports such as European Public Assess-
ment Reports (EPARs). The MCC refers to pharmacovigilance
reports and confirms GMP status and product compliance dur-
ing the review process. Although registration elsewhere is not a
prerequisite for making an application, information on existing
registrations should be provided, where available.
Part II: South African Regulatory Review Process
The South African regulatory review process is presented in
Figure 1. The review process map illustrates the main steps in
the review process and identifies the key milestone dates for
monitoring and analyzing timelines for review. The map pro-
vides a simple representation of the review and authorization of
applications for NASs and MLEs that are approved on the first
cycle. The map does not describe the process, in the event that
the application was refused. The appeal process that may be
initiated, following refusal of an application, has also not been
included in the review process map.
Queue Time
Applications for NASs are received by the Operations and
Administration Unit, and administrative screening of applica-
tions is performed within 15 calendar days from the time of
receipt. Applications are routed to the relevant unit, where they
are allocated to an assessor to start the review process. There is
no target set for the overall review time of an NAS application
and there are no targets set for the key milestones identified in
the review process. There is a mechanism in place whereby
priority applications may be fast-tracked. Products that will
be considered for expedited review are medicines on the Essen-
tial Drugs List (EDL) and new molecular entities that are con-
sidered essential for national health but that do not appear on
the Essential Drugs List.13 Scientific data requirements do not
differ between fast-track and other products, and the level of
scientific assessment is the same. Once submitted, however,
such products are always given priority in the queuing system,
and an overall target of 250 calendar days is set for fast-track
products. Currently, there is a substantial backlog because of
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Figure 1. Regulatory review process map for South Africa. Days reflected are calendar days. NAS, new active substance.
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the large number of applications received for the registration of
generic medicines; however, applications for NASs are not
placed in the same queue as generic medicine applications but
are routed for allocation to assessors on completion of admin-
istrative screening.
Scientific Assessment
Scientific data presented in applications are assessed in parallel
for quality, safety, and efficacy by different units within the
MCC. The assessments are performed by internal as well as
external assessors. While internal assessors are subject to annual
performance appraisals, the external assessors are not contrac-
tually bound by service-level agreements, and this condition has
an impact on review times. Detailed assessment reports and
recommendations are prepared by the assessors, and these are
peer reviewed and made part of the agenda at the relevant
Scientific Committee meetings for discussion. The Scientific
Committee then makes a recommendation to the MCC for rati-
fication. Although there is no set timeline for the scientific
assessment of applications, a request is sent to assessors to sup-
port completion of the assessment within 90 calendar days.
Questions to Sponsor (Applicant)
Recommendations pertaining to quality data are sent to spon-
sors, following ratification by the MCC. Sponsors who have
submitted an application for an NAS are requested to provide a
response to the recommendations within 180 calendar days.
The response from the sponsor will be reviewed by an assessor
and made part of the agenda at the next Scientific Committee
meeting and subsequent Council meeting.
Questions pertaining to safety and efficacy data may be
provided to the sponsor at any time during the assessment.
Recommendations from the Scientific Committee are sent to
the sponsor prior to ratification by the Council. Sponsors are
required to respond to the recommendations within 180 cal-
endar days. In the event that major deficiencies are identified
in the data submitted, the response from the sponsor will be
subjected to the full procedure of evaluation, discussion at the
Scientific Committee meeting, and ratification at the Council
meeting. The MCC has accepted responses that exceed the
time limit.
Expert Committees
Applications for an NAS are referred to a number of Scien-
tific Committees, which require at least 4 Committee reports
to be available prior to the medicine’s consideration for
registration by the MCC. These include the Pharmaceutical
and Analytical Committee, the Clinical Committee, Good
Compliance (eg, Good Manufacturing Practices, Good Dis-
tribution Practices, Good Clinical Practices, Good Labora-
tory Practices) Committee, and the Names and Scheduling
Committee. There is no target time limit for the Committee
procedure; however, routine committee meetings are held
every 60 calendar days. Committee processes are conducted
in parallel to support efficiencies in the review process.
Council meeting dates are scheduled to accommodate the
work of the Committees and prevent delays between the
outcome of Committee meetings and Council ratification.
The recommendations made by the Committees are made
part of the agenda at the Council meeting, and the Council
is responsible for the decision as to whether to grant author-
ization. This decision is based on the scientific assessment
of the quality, safety, and efficacy data submitted by the
sponsor. The Council will also base the decision for author-
ization or refusal on the approval of the proprietary name of
the product, the allocation of a scheduling status to the
active pharmaceutical ingredients, and the evaluation of the
GMP status of the sponsor, the manufacturer, the assembler,
the quality control laboratory, and the final product release
responsibility. The decision for authorization or refusal is
neither dependent on sample analysis nor on a pricing agree-
ment. Based on the timing of the Council meetings, the
authorization process can take up to 60 calendar days from
receiving a positive recommendation from the Scientific
Committees. Sponsors are informed of the decision of the
Council within 7 calendar days after the Council meeting,
and the target timelines for the MCC review process can be
seen in Table 1.
The majority of NASs approved over the period 2015-
2017 were submitted by international companies, while
local companies were responsible for 21% of these
approvals. The number of approved NASs from interna-
tional and local companies during the period 2015-2017 is
shown in Figure 2.
During the studied time period, the highest number of
approved NASs for international companies was 34 in 2017,
while the highest number of approved NASs for local compa-
nies was 8, in both 2015 and 2017. The highest number of
NASs was approved in 2017 (n ¼ 42), with a median approval
time of 1411 calendar days for applications made by interna-
tional companies and 1470 calendar days for applications made
by local companies (Figure 3). In 2016, 33 NASs were
approved, and in 2015, 31 NASs were approved. During the
period 2015-2017, the highest median approval time (1810
Table 1. Target Timelines for MCC Review Procedures.
Process Target
Validation 15 calendar days
Scientific assessment 90 calendar days
Sponsor response time (quality data) 180 calendar days
Sponsor response time (safety and efficacy
data)
180 calendar days
Expert committee(s) 60 calendar days
Authorization procedure 60 calendar days
Notification of decision 7 calendar days
Overall review time (fast track) NASs: 250 calendar
days
Overall review time NASs: No target
Abbreviations: MCC, Medicines Control Council; NASs, new active substances.
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calendar days) was observed in 2016, for applications made by
international companies. The lowest median approval time
(1086 calendar days) was also observed in 2016, for applica-
tions made by local companies (Figure 3).
In 2015 and 2016, the approval times for biological prod-
ucts were longer than for NASs (Figure 4). However in 2017,
the median approval time for biological products (n ¼ 5) was
less than for NASs (n ¼ 31). In 2016 and 2017, fast-track
products had shorter approval times in comparison to NASs.
Fast-track products also had shorter approval times in 2015-
2017, when compared with biologicals. In 2015 and 2017,
MLEs had the shortest approval times, when compared with
NASs, biologicals, and fast-track products. The most com-
monly approved NASs, by therapeutic class, during the
period 2015-2017 included cytostatic agents (14 products);
analgesics (8 products); anticonvulsants, including antiepi-
leptics (6 products); and nonsteroidal anti-inflammatory
drugs (6 products). During this time period, only 1 NAS per
class was approved for local anesthetics, vasoconstrictors,
ophthalmic preparations, medicines against protozoa, and
macrolides and lincosamides.
Part III: Good Review Practices: Building Quality into the
Registration and Review Processes
General Measures Used to Achieve Quality
The MCC has developed an internal quality policy that
describes the overall intentions and direction of the authority,
related to the quality of the review process. Within the next 2
years, the authority intends to formally implement a quality
policy and prescribe the measures that will be used to achieve
and continuously improve quality. GRevPs are defined as a
framework, applied to the process and documentation related
to regulatory review procedures. GRevP measures aim to stan-
dardize and improve overall documentation and to ensure time-
liness, predictability, consistency, and high quality in reviews
and assessment reports. The MCC has initiated the develop-
ment and implementation of a GRevP framework; however, it
is acknowledged that the system is still evolving. Table 2 pro-
vides an overview of the status of the implementation of
GRevPs by the MCC and demonstrates that there are a number
of elements of the framework that need to be formalized and
improved.
The MCC has also recognized that the currently implemen-
ted elements of the GRevP framework have been underused by
staff. Additional training to learn and understand GRevPs
would be valuable so that the benefits of formally implement-
ing a comprehensive GRevP framework within the authority
may be fully realized. Furthermore, the MCC intends to for-
mally codify the critical elements of GRevPs so that they may
be written into the internal organizational policy. The authority
also aims to develop a quality management system to support
the successful application of GRevPs. Standard operating pro-
cedures (SOPs) are available to describe the routine procedure
for the regulatory review process, and these provide guidance
for the scientific assessors and the advisory committee who are
consulted during the review process. These need to be revita-
lized to provide a detailed description of processes that have
been enhanced, and there are plans to update these SOPs within
the next 2 years.
Assessment templates, which set out the content and format
of written reports on scientific reviews, are available and both
external and internal peer reviews are carried out when an NAS
is assessed. Elements included in this assessment template are
drug substance, drug product, comments on the product label,
nonclinical data, clinical pharmacology, safety and efficacy,
good clinical practice aspects, and a list of recommendations
to the sponsor.
The scientific committees involved in the regulatory review
process meet approximately every 60 calendar days to review
NAS applications. The assessment reports discussed at these
meetings are prepared by both internal and external assessors,
but these are not published on the MCC website. The recom-
mendations made by the scientific committees are made part of
the agenda at the MCC meeting, where the decision for accep-
tance or refusal of the application is made.
Figure 2. Number of approved new active substances from local and
international companies (2015-2017).
Figure 3. Median approval timelines for new active substances for
local and international companies (2015-2017).
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Table 2. Status of Implementation of Good Review Practices by the MCC.
Indicator Status Comments
Quality measures
Internal quality policy P Planned to formally implement
Good review practice system P Planned to formally implement
Standard operating procedures for guidance of assessors P Planned to formally implement
Assessment templates P Planned to formalize the use of a single, common template
Dedicated quality department O Establishment of a dedicated quality department is planned
Scientific committee P
Shared and joint reviews P
Transparency and communication parameters
Feedback to industry on submitted dossiers P
Details of technical staff to contact P Contact details are made available on an ad hoc basis
Presubmission scientific advice to industry P Meetings are held with industry on an ad hoc basis
Official guidelines to assist industry P
Industry can track progress of applications O Implementation of electronic document management system is planned
Publicly available Summary Basis of Approval (SBA) O Summary is available but is currently not published
Approval times P Approval times are not made available to the public
Advisory committee meeting dates P
Approval of products P
Continuous improvement initiatives
External quality audits P External quality audits are not performed routinely
Internal quality audits O Planned
Internal tracking systems P Implementation of electronic document management system is planned
Review of assessors’ feedback P
Reviews of stakeholders’ feedback P Planned to be formally and routinely reviewed
Training and education
International workshops/conferences P
External courses P
In-house courses P Training program to be formalized
On-the-job training P Training program to be formalized
External speakers invited to the authority P
Induction training P Training program to be formalized
Sponsorship of postgraduate degrees P
Placements and secondments in other regulatory authorities P
& Formally implemented
& Informally implemented
&Not implemented
Figure 4. Median approval time for new active substances compared with biologicals, major line extensions, and fast track products
(2015-2017).
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Quality Management
The MCC recognizes the importance of introducing quality
measures throughout the authority in order to ensure consis-
tency, increase transparency, improve efficiencies, and
enhance allocation of regulatory resources. The MCC holds
regular meetings with external stakeholders, in the form of
Industry Task Group (ITG) meetings, which provide a forum
for candid discussion between the industry and the regulator.
The MCC maintains an open-door policy, whereby meetings
with the regulator are routinely facilitated. Furthermore, the
industry and interested parties are invited to participate in
workshops hosted by the regulator, through which opinions,
feedback, and complaints may be received and channeled into
corrective and preventive actions.
Currently, the MCC does not have a dedicated unit for
assessing the quality of the review process for new medicines;
however, contingencies have been put in place to establish
such a unit. This unit will be responsible for developing a
quality system for the authority, for performing internal qual-
ity audits, and for implementing strategies geared for contin-
uous improvement, through retrospective evaluation of the
assessment and authorization process. Provision has also been
made to employ the use of an electronic document manage-
ment system (EDMS). The tracking functionality of the
EDMS will allow for internal monitoring of the process, thus
contributing to efficiency and accuracy in the review process.
The quality unit will also be responsible for ensuring that the
requirements of the quality management system of the author-
ity are fulfilled, in order to be certified to the quality standards
of the International Standardization Organization (ISO) and to
ensure that the South African regulatory system is recognized
by the WHO.
Quality in the Review and Assessment Process
The MCC has implemented a number of mechanisms in an
effort to improve the quality of applications received from
sponsors and the scientific review of such applications. Guide-
lines for industry have been developed and have been published
on the MCC website and in official publications. These guide-
lines are also available on request from the regulator and
through industry associations. There is no policy for providing
preapplication scientific advice to a sponsor, and such advice is
not routinely monitored. Preapplication scientific advice may
be provided following a request from the sponsor, who is also
given the contact details of technical staff who may be con-
tacted to discuss an application during the review. Formal con-
tact, such as scheduled meetings with the regulator, is possible
during product development and assessment and in this time
there is also an extensive amount of informal contact between
the sponsor and the regulator, via telephone or email.
Shared and Joint Reviews
The MCC takes part in joint reviews through the ZaZiBoNa
collaborative process that aims to harmonize regulatory efforts
across Africa. The process started as a partnership between the
regulatory authorities in Zambia, Zimbabwe, Botswana, and
Namibia, and participation by interested South African Devel-
opment Community (SADC) Member States is encouraged.14
In order to be eligible to participate in the ZaZiBoNa colla-
borative process, the sponsor is required to submit the applica-
tion for registration to 2 of the participating authorities.13
Products that have been registered by recognized regulatory
authorities are eligible for an abridged review process provided
that the assessment report from the authorizing authority is
available. The collaborative process aims to complete product
authorization or refusal within 11 months. Products may be
considered for 2 review cycles, and sponsors are required to
respond to the consolidated list of regulatory assessment ques-
tions within a period of 60 days. The overall review target for
the collaborative process is 210 days. Participating regulatory
authorities maintain the right to make a final determination on
any application, and the final national regulatory decisions are
the responsibility of individual participating authorities.14
Training and Education
Training and professional development of internal and external
assessors continues to contribute to the element of quality
within the MCC review process (Table 2). Although the train-
ing program has not been formalized, assessors are required to
take part in induction and on-the-job training. Mentorship pro-
grams between experienced assessors and less experienced
assessors have been developed to provide support. The
National Department of Health provides financial support to
assessors enrolled in postgraduate studies and external courses.
Assessors have the opportunity to be seconded to other regu-
latory authorities for further training and regularly attend inter-
national workshops and conferences to enrich their learning.
Participation in training provided by the WHO, on topics such
as the prequalification process and quality managements sys-
tems, as well as training provided by the European Directorate
for the Quality of Medicine has formed an integral part in the
training of assessors.
Transparency of the Review Process
The MCC assigns a high priority to being open and transparent
in relationships with the public, health professionals, and
industry. The MCC has recognized the need to increase confi-
dence in the regulatory system and to provide assurances on
safety safeguards as the main drivers for assigning resources to
activities that enhance the transparency of the regulatory sys-
tem. Table 2 provides an overview of the measures that have
been put into place by the MCC in an effort to promote trans-
parency and improve communication with stakeholders.
The MCC has a manual system in place that is used to trace
applications that are under review and identify the stage at
which the application is in the process. Currently, sponsors are
able to track the status of their applications, via telephone and
email contact, but the MCC is progressing toward the use of an
EDMS that is capable of signaling any target review dates that
may have been exceeded, recording the terms of the
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authorization once granted, and providing searchable archiving
of information on applications. The MCC publishes the list of
licensed manufacturers, wholesalers, and quality control
laboratories; committee meeting dates; and a list of registered
products, on the MCC website, where such relevant informa-
tion is published in the Government Gazette.
Discussion
The regulatory authority in South Africa strives to be an author-
ity of international standing and is one of the most developed
authorities in the African region. The authority has taken into
account international best practices in the development of its
legislation, guidelines, and SOPs. Regulatory authorities in
low- and middle-income countries continuously face a number
of challenges and are often not sufficiently resourced to pro-
vide an efficient and effective service. The MCC has histori-
cally faced similar difficulties, resulting in a track record of
slow decision making and unnecessary delays in effecting reg-
ulatory mandates. Currently review times for NASs are in
excess of 4 years, whereas for mature agencies this is of the
order of 10 to 16 months.15 This subsequent delay with respect
to patients’ access to new medicines is the rationale for the
establishment of the new regulatory authority, SAHPRA, and
the re-engineering of the current regulatory processes in South
Africa. The success of the new system is imperative as the
South African authority strives to be considered alongside
other comparable agencies.
This study evaluated the overall regulatory approval times for
NASs, biologicals, MLEs, and fast-track applications in South
Africa from 2015-2017. The number of products approved by
the MCC has been increasing each year, and during 2015-2017,
79% were sponsored by international companies. While local
companies do submit applications for NASs, these companies
often do not have the resources and dedicated research facilities
to develop such products in-house, but rather enter into contrac-
tual agreements with international companies to develop the
products abroad or to sell the product under license.
Significant pro-access policies, which were implemented
historically by the Department of Health to support medicine
access by the state sector, have resulted in an inundation of
generic medicine applications, notwithstanding the number of
registered products of the same molecule already available on
the market. Efforts to address the increasing volume of appli-
cations that have been received have to date failed and resources
have been stretched to capacity, resulting in the development of
a significant backlog and extended timelines for product regis-
tration. Furthermore, inappropriate operational processes and a
structure that is heavily reliant on overcommitted external
assessors and devoid of effective performance contracts do not
provide a sustainable solution for timely evaluations.
The MCC has recognized the importance of building confi-
dence into the system and the support from expert review com-
mittees as factors that may contribute to the effectiveness and
efficiency of the review and decision-making processes for
NAS applications. While outdated mechanisms for review
could be improved through the re-engineering of the opera-
tional process and decision model, consideration of an appro-
priate benefit-risk model is recommended. With the
amendment of the Medicines and Related Substances Act,
1965 (Act 101 of 1965) in support of liaising with other reg-
ulatory authorities, in the spirit of harmonization, the MCC
could consider the use of an alternative risk stratification model
incorporating reliance strategies on other regulatory authori-
ties. It is also evident that firm target times for the review
process must be written into the organizational policy and
should be tracked through the use of an electronic management
system in order to realize effective regulatory mandates.
Conclusions
This study has evaluated the current MCC regulatory review
process, as it has been applied prior to the establishment of
SAHPRA. Key milestones and timelines within the regulatory
review process have been identified and the measures used for
GRevP have been considered. Currently the MCC continues to
perform a full review assessment for applications for registra-
tion, including NASs and generics for orthodox, biological,
complementary, and veterinary medicinal products. The value
added in codifying the guidelines for GRevP and formalizing
the quality policy and quality management system have been
recognized. The findings from this study suggest that the MCC
has identified the opportunities for an enhanced regulatory
review and may consider an abridged assessment model, which
encompasses elements of risk stratification and reliance. As the
MCC transitions to the newly established SAHPRA it is hoped
that the resource constraints may be alleviated and capacity
developed to meet target timelines. The intersection of regula-
tory frameworks, regulatory performance, and improved
access, availability, and affordability of quality, safe, and effec-
tive health care products in South Africa has become an essen-
tial area for advancement. In the light of the findings of this
study, the evaluation of the regulatory environment in South
Africa with a view to improving the review process and
patients’ access to medicines will be prioritized.
Acknowledgments
The authors acknowledge the assistance of the Deputy Director: Oper-
ations and Administration of the Medicines Control Council, for the
collection of the data pertaining to metrics on the approval process for
new active substances.
Declaration of Conflicting Interests
Andrea Keyter was employed by the South African National Depart-
ment of Health in the Cluster: Food Control, Pharmaceutical Trade
and Product Regulation during the time of this study. Dr Joey Gouws
was the Registrar for the Medicines Control Council and was
employed by the South African National Department of Health in her
capacity as Acting Cluster Manager: Food Control, Pharmaceutical
Trade and Product Regulation during the time of this study.
Keyter et al 457
Funding
The authors did not receive any financial support for carrying out this
work.
ORCID iD
Sam Salek, RPh, PhD, FFPM, FRPS, MCMS, FESCP http://orci
d.org/0000-0002-4612-5699
References
1. Ratanawijitrasin S, Wondemagegnehu E. Effective Drug Regula-
tion: A Multi-country Study. Geneva: World Health Organization;
2002.
2. Hill S, Johnson K. Emerging challenges and opportunities in drug
registration and regulation in developing countries, DFID Issue
Paper, 2004. http://heart-resources.org/wp-content/uploads/2012/
10/Emerging-challenges-and-opportunities-in-Drug-registration-
and-regulation.pdf. Accessed November 5, 2017.
3. Cone M, Walker S.Workshop Report: Building Quality Into Reg-
ulatory Dossiers and the Review Process: Knowing and Meeting
Customer Expectations. Surrey, UK: CMR International Institute;
2005.
4. Cone M, McAuslane N. R&D Briefing 46: Building Quality Into
Regulatory Activities: What Does It Mean? Epsom, UK: CMR
International Institute, 2006.
5. Al-Essa R, Salek S, Walker S. An appraisal of good regulatory
review practices in the Gulf Cooperation Council States. Drug
Info J. 2012;46:57.
6. World Health Organization. Good review practice guidelines
for regulatory authorities (draft for comment). 2014. http://
www.who.int/biologicals/GRevPGuidelines-RHSC-endorsed-
for-WHO_QAS14-576_27022014.pdf. Accessed November 5,
2017.
7. Soomaroo S. The Department of Trade and Industry’s involve-
ment in the State’s procurement of ARVs. Presented to the Port-
folio Committee on Economic Development, Pretoria, South
Africa, 2017. https://www.thedti.gov.za/parliament/2017/Pharma
ceuticals.pdf. Accessed November 3, 2017.
8. Medicines Control Council. Publications. http://www.mccza.
com/About. Accessed October 29, 2017.
9. Medicines Control Council. Business Plan, 2006.
10. Republic of South Africa. Medicines and Related Substances
Act, 1965 (Act 101 of 1965). Government Gazette 40869, May
26, 2017.
11. National Treasury. Guide for creating, merging, rescheduling and
disestablishment of entities on the national or provincial sphere of
government, 1 December 2015.
12. McAuslane N, Cone M, Collins J, Walker S. Emerging markets
and emerging authorities: a comparative study of how key regu-
latory authorities in Asia, Latin America, the Middle East and
Africa are developing regulatory processes and review models for
new medicinal products. Drug Info J. 2009;43:349-359.
13. Medicines Control Council. General Guideline: Registration of
Medicines, version 8, August 2012. http://www.mccza.com/docu
ments/1d9c57df2.01_General_information_Jul12_v8_showing_
changes.pdf. Accessed November 2, 2017.
14. Regulatory Resources for Africa. ZAZIBONA Registration Path-
way, version 1, 9 June 2015. http://www.rrfa.co.za/harmonisa
tion/. Accessed November 3, 2017.
15. Centre for Innovation in Regulatory Science. R&D Briefing 65:
New drug approvals in six major authorities 2007-2016: Focus on
the internationalisation of medicines. 2017, London.
458 Therapeutic Innovation & Regulatory Science 52(4)
